Лечение урогенитальных инфекций у беременных женщин и внутриутробного инфицирования у новорожденных детей препаратами рекомбинантного интерферона альфа-2b: результаты мета-анализа

Abstract

We summarized the results of 35 studies published in the last 25 years that evaluated the efficacy and safety of human recombinant interferon alpha-2b (Viferon®) in the treatment of inflammatory genitourinary infections in pregnant women and intrauterine infections in newborns. This drug has a positive effect on clinical manifestations and disease outcome; it promotes the elimination of pathogens, reduces the frequency and duration of viral/bacterial shedding and recurrent infections; it also prevents coinfection with other pathogens; reduces infection-associated morphological changes of the placenta and improves its morphometric parameters; restores normal uteroplacental blood flow, reduces the risk of placental insufficiency and intrauterine hypoxia; it significantly changes the colposcopy pattern, restore vaginal microbiocenosis, substantially reduces the incidence of infectious and inflammatory complications in mothers and incidence of intrauterine infections (including severe ones) in newborns; it decreases the length of stay in hospital and intensive care unit, duration of artificial ventilation, parenteral nutrition, antibacterial therapy in newborns with pneumonia; significantly reduces the frequency of perinatal non-infectious disorders; it improves the immune parameters, including those associated with antiviral protection, as well as the cytokine status in pregnant women with genitourinary infections and newborns with intrauterine infections; the drug caused no side effects or adverse reactions. Key words: pregnant women, intrauterine infection, newborns, recombinant interferon alpha-2b, urogenital infections